Introduction
Perimenopause represents a transitional reproductive phase characterized by fluctuating ovarian hormone levels preceding menopause. Unlike menopause, which is defined as permanent cessation of menses for 12 months, perimenopause is a clinically heterogeneous period marked by irregular menstrual cycles, variable symptomatology, and distinct pathophysiology. This stage often presents significant management challenges for clinicians due to its variable presentation, uncertain duration, and overlapping symptoms with other conditions.
Clinical Context and Unmet Needs in Perimenopause
Perimenopause affects a considerable proportion of women typically in their late 40s to early 50s, with symptoms ranging from vasomotor disturbances and mood changes to abnormal uterine bleeding. These symptoms can markedly reduce quality of life. However, current clinical guidelines lack specific recommendations tailored to the perimenopausal phase, resulting in variability in practice and unmet patient needs. Additionally, management decisions are complicated by considerations related to contraception, as ovulation may still be intermittent, and by evolving cardiometabolic risk profiles associated with aging and hormonal changes. Hence, clinicians must adopt an individualized approach that incorporates comprehensive patient evaluation.
Hormonal Contraceptives in Perimenopause
Hormonal contraceptives are often prescribed during perimenopause to address both contraception and symptom relief. Combined oral contraceptives (COCs) remain a mainstay due to their ability to regulate menstrual cycles, reduce heavy bleeding, and alleviate vasomotor symptoms. Progestin-only options and extended-cycle regimens offer alternatives depending on patient tolerance and risk factors. However, hormonal contraceptives are not universally effective or preferred; contraindications such as cardiovascular risk factors and patient preferences may limit their use. Safety concerns, including thromboembolic risk, particularly in older perimenopausal women or smokers, necessitate careful patient selection and counseling.
Alternative Hormonal Strategies
Beyond contraceptives, other hormonal therapies have roles in symptom management during perimenopause. These include low-dose estrogen therapy, localized vaginal estrogen for genitourinary symptoms, and selective estrogen receptor modulators (SERMs). Tailoring hormonal therapy involves balancing benefits in symptom relief against risks such as endometrial hyperplasia or thromboembolic events. For women with abnormal uterine bleeding, progestogen therapy or levonorgestrel-releasing intrauterine systems (LNG-IUS) may be particularly effective. The timing and dosage of hormone therapy require adjustment reflecting the patient’s symptom severity, comorbidities, and personal risk factors.
Individualizing Management Through Shared Decision-Making
Shared decision-making is essential given the complex interplay of symptomatology, contraceptive needs, cardiovascular and cancer risks, and patient preferences. A thorough history and examination to characterize symptoms, menstrual patterns, and risk stratification enable personalized treatment plans. Clinicians should educate patients about the benefits, risks, and alternatives of hormonal options and discuss lifestyle measures supportive of overall health including diet, exercise, and smoking cessation. Ongoing monitoring for symptom response and adverse events allows treatment modification or escalation as needed.
Clinical Perspectives and Recommendations
This clinician toolkit emphasizes the need to recognize perimenopause as a distinct physiological state warranting individualized assessment. Hormonal contraceptives remain an important therapeutic option for combined symptom management and contraception but require careful selection. Alternative hormonal agents and non-hormonal options expand the therapeutic armamentarium. Incorporating evidence-based risk stratification and patient-centered communication underpins optimal outcomes. Further research is needed to generate specific guidelines addressing perimenopause hormonal management and long-term safety profiles.
Conclusion
Managing perimenopause demands nuance given its clinical heterogeneity and unique physiological characteristics. Hormonal therapies, including contraceptives and alternative strategies, provide vital symptom relief and reproductive planning options but are not one-size-fits-all solutions. A practical, patient-tailored toolkit that integrates hormonal options with individualized risk assessment and shared decision-making can improve care quality and patient satisfaction. Ongoing education and research will strengthen evidence and guide more precise recommendations for this critical reproductive transition.
References
1. Piasta J, Zewail A. Hormonal Options for Perimenopause: A Clinician Toolkit. Obstetrics and Gynecology. 2026 Sep 15; PMID: 42743436.
2. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015 Mar;44(1):497-515.
3. North American Menopause Society. The 2020 hormone therapy position statement of The North American Menopause Society. Menopause. 2020 Jul;27(7): 592-608.
4. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015 Mar 3;(3):CD002229.
